Biophysical Characterization of Binary Therapeutic Monoclonal Antibody Mixtures

被引:7
|
作者
Krieg, Dennis [1 ]
Berner, Carolin [1 ]
Winter, Gerhard [1 ]
Svilenov, Hristo L. [1 ,2 ]
机构
[1] Ludwig Maximilians Univ Muenchen, Dept Pharm Pharmaceut Technol & Biopharmaceut, D-81377 Munich, Germany
[2] Tech Univ Muenchen, Dept Chem, D-85747 Garching, Germany
关键词
monoclonal antibodies; antibody mixtures; coformulation; stability; biophysical properties; VISCOSITY BEHAVIOR; CHARGE VARIANTS; LIQUID-LIQUID; PROTEIN; COAGGREGATION; PREDICTION; STABILITY; SEQUENCE; GOVERN; TOOL;
D O I
10.1021/acs.molpharmaceut.0c00370
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Coformulations containing two therapeutic monoclonal antibodies (mAbs) could offer various benefits like enhanced therapeutic efficacy and better patient compliance. However, there are very few published studies on coformulations and binary mixtures of mAbs. It remains unclear to what extent mAbs with different physicochemical properties can be combined in solution without detrimental effects on protein stability. Here, we present a study including six model mAbs of the IgG1 subclass that are commercially available. In silico and biophysical characterization shows that the proteins have different physicochemical properties. Thus, their combinations represent various scenarios for coformulation development. We prepared all possible binary mixtures of the six mAbs and determined several biophysical parameters that are assessed during early-stage protein drug product development. The measured biophysical parameters are indicative of the conformational protein stability (inflection points of the thermal protein unfolding transitions) and the colloidal protein stability (aggregation onset temperatures and interaction parameter k(D) from dynamic light scattering). Remarkably, all 15 binary mAb mixtures do not exhibit biophysical parameters that indicate inferior conformational or colloidal stability compared to the least stable mAb in the mixture. Our findings suggest that the coformulation of some therapeutic monoclonal antibodies of the IgG1 subclass could be possible in a straightforward way as severe detrimental effects on the stability of these proteins in binary mixtures were not observed.
引用
收藏
页码:2971 / 2986
页数:16
相关论文
共 50 条
  • [41] Biophysical Characterization of Therapeutic Proteins for Early Prediction of Manufacturability
    Chakroun, Nesrine
    Hilton, David
    Daldy, Paul A.
    BIOPHYSICAL JOURNAL, 2014, 106 (02) : 668A - 668A
  • [42] PRODUCTION OF MULTIPLE LOTS OF THERAPEUTIC MONOCLONAL-ANTIBODY
    GILBRIDE, KJ
    SAMIOTES, D
    KERTILES, L
    DUFF, RG
    FEDERATION PROCEEDINGS, 1985, 44 (05) : 1685 - 1685
  • [43] Impact of monoclonal antibody drugs on recent therapeutic progress
    Renedo Miro, B.
    Munne Garcia, M.
    Juarez Gimenez, J. C.
    Montoro Ronsano, J. B.
    JOURNAL OF BIOTECHNOLOGY, 2010, 150 : S439 - S439
  • [45] THE MONOCLONAL-ANTIBODY MARKET - AWAITING THEIR THERAPEUTIC EFFICIENCY
    VINCENT, C
    LATRILLE, F
    LATRILLE, J
    BIOFUTUR, 1990, (90) : 64 - &
  • [46] Applications on therapeutic monoclonal antibody analysis by capillary electrophoresis
    Chen Hongxu
    Qu Feng
    CHINESE JOURNAL OF CHROMATOGRAPHY, 2018, 36 (03) : 195 - 208
  • [47] Affinity search for free thiols in a therapeutic monoclonal antibody
    Wilkes, E
    Quan, C
    Ma, S
    PROTEIN SCIENCE, 2004, 13 : 153 - 153
  • [48] Therapeutic monoclonal antibody concentration monitoring: free or total?
    Kuang, Bing
    King, Lindsay
    Wang, Huifen Faye
    BIOANALYSIS, 2010, 2 (06) : 1125 - 1140
  • [49] Therapeutic monoclonal antibody interference in electrophoretic and immunofixation techniques
    Sahinovic, I.
    Sincic-Petricevic, J.
    Orsic-Fric, V.
    Borzan, V.
    Pavela, J.
    Fijacko, M.
    Seric, V.
    CLINICA CHIMICA ACTA, 2019, 493 : S45 - S46
  • [50] Trends in capacity utilization for therapeutic monoclonal antibody production
    Langer, Eric S.
    MABS, 2009, 1 (02) : 151 - 156